Investor Relations

Recent Event

BIO International Convention

Latest Financial Results

Q1 2024

Quarter Ended Mar 31, 2024

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX is available at

Stock Snapshot

XORTX Therapeutics Inc.

View Detailed Stock Information

IR Contacts


XORTX Therapeutics Inc.
3710 – 33rd Street NW
Calgary, Alberta T2L 2M1
T: 403-455-7727

Investor Relations

Allen Davidoff
T: 403-455-7727

Nick Rigopulos
Director of Communications
T: 617-901-0785

Transfer Agent

TSX Trust Company
Investor Services
100 Adelaide Street West
Suite 301
Toronto, ON M5H 4H1
T: 416-342-1091